Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Marie-Luise Berres, Stephan L. Chan,Masatoshi Kudo,Bruno Sangro,Robin Kate Kelley,Junji Furuse,Joong-Won Park, Patrapim Sunpaweravong,Angelica Fasolo,Thomas Yau,Tomokazu Kawaoka, Ann-Li Cheng,Sergio Azevedo,Maria Reig,Eric Assenat,Mark Yarchoan, Aiwu R He,Mallory Makowsky, Di Ran,Alejandra Negro,Ghassan Abou-Alfa

Zeitschrift Fur Gastroenterologie（2023）

引用 0|浏览1

暂无评分

摘要

Background In HIMALAYA (NCT03298451), a single, high priming dose of tremelimumab plus durvalumab (STRIDE) significantly improved overall survival (OS) vs sorafenib, and durvalumab was noninferior to sorafenib in uHCC (Abou-Alfa et al. 2022). Viral aetiology is associated with hepatic impairment in HCC development and may influence immunotherapy activity. Thus, we analysed the impact of viral aetiology on clinical outcomes.

查看译文

关键词

hepatocellular carcinoma,unresectable hepatocellular carcinoma,viral aetiology,durvalumab,tremelimumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要